ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.”
Andrew Newland
Chief Executive

ANGLE is a world leading liquid biopsy company with sample to answer solutions.

ANGLE’s proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE has launched a product for the research use market and has an In-vitro Diagnostic Devices Directive CE Mark for the indicated clinical use. The FDA clearance process is currently underway for the clinical market in the US.

ANGLE welcomes Axela team and technology, now known as ANGLE Biosciences to the ANGLE group of companies.Read more here